NYSE:BIOLife Sciences
Bio Rad Laboratories (BIO) Stock Looks Fairly Valued After A 57% Slide
Bio-Rad Laboratories has produced a mixed experience for long term shareholders, with the stock down about 57.1% over five years, yet recent trading leaves it looking neither clearly cheap nor clearly expensive when compared with estimates of intrinsic value and market multiples.
Over the past five years, Bio-Rad Laboratories’ share price has declined around 57.1%, which highlights how sensitive long term returns can be to the price paid versus the company’s fundamentals.
The launch of...